Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation - A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Warfarin

NCT00448214 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00448214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00448214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation - A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Warfarin
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
October 31, 2008
Enrollment
448 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation